Press Releases April 20, 2026 08:00 PM

embecta to Report Fiscal Second Quarter Financial Results

Embecta Corp. Announces Upcoming Fiscal Q2 2026 Earnings Call and Operational Update

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
EMBC

Embecta Corp. will report its fiscal second quarter 2026 financial results in a conference call scheduled for May 5, 2026. The company will also provide an operational update and host a Q&A session. Embecta is continuing its transition from an insulin delivery company to a broad-based medical supplies company with a global presence.

embecta to Report Fiscal Second Quarter Financial Results
EMBC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Embecta will release Q2 2026 financial results on May 5, 2026, with a public earnings call and Q&A session.
  • The company is evolving from a focus on insulin delivery toward becoming a broader medical supplies company.
  • Embecta employs approximately 2,000 people globally and leverages a century-long legacy in insulin delivery.

PARSIPPANY, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal second quarter 2026 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Tuesday, May 5, 2026.

Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.embecta.com.

A webcast replay of the call will be available beginning at 11:00 a.m. ET on May 5, 2026, via the embecta investor relations website and archived on the website for one year.

About embecta 

embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram.

Contacts:
  Media
Christian Glazar
Sr. Director, Corporate Communications
908-821-6922                                                                            
Contact Media RelationsInvestors
Pravesh Khandelwal
VP, Head of Investor Relations
551-264-6547
Contact IR  

Risks

  • Financial performance unknown until earnings release, creating potential volatility around the earnings call.
  • Transitioning business model may face execution risks as the company broadens its product portfolio beyond insulin delivery.
  • Global operations may be impacted by supply chain disruptions or regulatory changes in the medical supplies sector.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026